Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Association of PDCD1 CTLA-4 Results from a Large and Pooled Microarray Database

Association of PDCD1 CTLA-4 Results from a Large and Pooled Microarray Database Original Atricle Association of PDCD1 and CTLA-4 Gene Expression with  Clinicopathological Factors and Survival in Non–Small-Cell  Lung Cancer Results from a Large and Pooled Microarray Database Lei Deng,*† Balazs Gyorffy, MD, PhD, MSc,‡§║ Feifei Na, MD,*† Baoqing Chen,*† Jie Lan, MD,* Jianxin Xue, MD, PhD,* Lin Zhou, MD,* and You Lu, MD* and current/former smokers. Higher expression of CTLA-4, but not Introduction: Immune checkpoint blockade is being investigated in PDCD1 predicts worse survival. clinical trials and showed great potential in lung cancer. The prognos- tic roles of and clinicopathological factors associated with immune Key Words: Non–small-cell lung cancer, Immune checkpoint checkpoint gene expression, CTLA-4 and PDCD1 remain largely blockade, PDCD1, CTLA-4, Smoking, Squamous carcinoma, undefined, which encodes cytotoxic-lymphocyte antigen 4 (CTLA-4) Adenocarcinoma, Prognosis, Microarray and programmed cell death 1 (PD-1), respectively. (J Thorac Oncol. 2015;10: 1020–1026) Methods: We used a lung cancer database of 1715 patients measured by Affymetrix microarrays to analyze the association of gene expres- sion with clinicopathological factors and survival. Hazard ratio (HR) on–small-cell lung cancer (NSCLC) is one of the leading and 95% confidence interval (CI) for overall survival (OS) were calcu- Ncancer death causes in the world. Despite recent prog- lated. Cutoffs were determined by median across the entire database. ress and newly approved drugs, prognosis of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Association of PDCD1 CTLA-4 Results from a Large and Pooled Microarray Database

Lu, You
Journal of Thoracic Oncology , Volume 10 (7) – Jul 1, 2015
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/association-of-pdcd1-ctla-4-results-from-a-large-and-pooled-microarray-kw0NQc9JFP

References (42)

Copyright
Copyright © 2015 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000550
pmid
26134222
Publisher site
See Article on Publisher Site

Abstract

Original Atricle Association of PDCD1 and CTLA-4 Gene Expression with  Clinicopathological Factors and Survival in Non–Small-Cell  Lung Cancer Results from a Large and Pooled Microarray Database Lei Deng,*† Balazs Gyorffy, MD, PhD, MSc,‡§║ Feifei Na, MD,*† Baoqing Chen,*† Jie Lan, MD,* Jianxin Xue, MD, PhD,* Lin Zhou, MD,* and You Lu, MD* and current/former smokers. Higher expression of CTLA-4, but not Introduction: Immune checkpoint blockade is being investigated in PDCD1 predicts worse survival. clinical trials and showed great potential in lung cancer. The prognos- tic roles of and clinicopathological factors associated with immune Key Words: Non–small-cell lung cancer, Immune checkpoint checkpoint gene expression, CTLA-4 and PDCD1 remain largely blockade, PDCD1, CTLA-4, Smoking, Squamous carcinoma, undefined, which encodes cytotoxic-lymphocyte antigen 4 (CTLA-4) Adenocarcinoma, Prognosis, Microarray and programmed cell death 1 (PD-1), respectively. (J Thorac Oncol. 2015;10: 1020–1026) Methods: We used a lung cancer database of 1715 patients measured by Affymetrix microarrays to analyze the association of gene expres- sion with clinicopathological factors and survival. Hazard ratio (HR) on–small-cell lung cancer (NSCLC) is one of the leading and 95% confidence interval (CI) for overall survival (OS) were calcu- Ncancer death causes in the world. Despite recent prog- lated. Cutoffs were determined by median across the entire database. ress and newly approved drugs, prognosis of

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jul 1, 2015

There are no references for this article.